Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the ...
| Ticker |
Sentiment |
Impact |
|
ASND
|
Neutral
|
10 %
|
|
RPRX
|
Somewhat Bullish
|
30 %
|
|
ABBV
|
Neutral
|
3 %
|
